[Drugs for Neglected Diseases initiative (DNDi)] Kinshasa / Paris / Geneva / Amsterdam -- · Recommendation based on Phase II/III study demonstrating up to 96 per cent success rates at 18 months across both early and advanced stages of T.b. gambiense, the most common form of sleeping sickness
LEGAL_NOTICE: This website acts solely as an automated content aggregator. We do not host, store, or upload any media shown above. All content is indexed via machine logic from external sources.